AbbVie (NYSE:ABBV) recently announced positive results from its Phase 3 TEMPLE study, marking significant progress in ...

(Reuters) -AbbVie said on Wednesday its migraine drug met the main goal and was superior to a widely used generic treatment ...

AbbVie's atogepant showed fewer side effects and greater efficacy than topiramate in a Phase 3 migraine prevention trial.

Shares of AbbVie (ABBV) were in the spotlight on Wednesday after the company announced positive results from a late-stage ...

AbbVie’s latest Phase 3 TEMPLE study delivers a real headache for migraines—and topiramate. The study found that patients ...

AbbVie said on Wednesday its migraine drug met the main goal and was superior to a generic drug in a head-to head late-stage ...

Health and Human Services Secretary Robert F. Kennedy Jr. wants to make it harder and more expensive for drug companies to advertise to patients.

Two Democratic lawmakers have renewed accusations that large pharma companies have evaded paying U.S. taxes through a ...

This was the stock's third consecutive day of losses.

The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...

Limiting pharma ads would be a major win for Health and Human Services Secretary Robert F. Kennedy Jr. He’s long wanted to ...

The Trump administration is discussing policies that would make it harder and more expensive for pharmaceutical companies to ...